trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['trastuzumab', 'bcsm', 'breast']
fam-trastuzumab deruxtecan-nxki doubles progression-free survival in her2-low metastatic breast cancer #bcsm #oncology #cancer #immunotherapy #asco22
News and views from the world of clinical oncology and hematology